

FAX RECEIVED

JUL 14 2003

GROUP 1600

POWDERJECT
PHARMACEUTICALS PLC

OFFICIAL

Fax To: Examiner R. P. Schwartz
United States Patent and Trademark Office
Group Art Unit 1645
Attn: MAIL STOP RCE

Fax No: (703) 308-4242

From: Thomas P. McCracken

Date: 11 July 2003

Re: Patent Application Serial No. 09/501,328

Pages: 26 (including this one)

Please deliver the attached documents (Request for Continued Examination (RCE) Transmittal, Petition for Extension of Time and Amendment), totaling with this cover sheet 26 pages, to the attention of MAIL STOP RCE (Group Art Unit 1645). Please make these documents of official record in U.S. Serial No. 09/501,328.

Respectfully submitted,

Thomas P. McCracken
Registration No. 38,548

POWDERJECT PHARMACEUTICALS PLC.
Florey House
The Oxford Science Park
Oxford OX4 4GA
United Kingdom
Tel: +44 1865 332 600
Fax: +44 1865 332 601

The information contained in this facsimile transmission is intended only for the person named above as addressee. It may contain information which is private and privileged, the disclosure of which is prohibited by law. If you have received this communication in error, please notify us immediately at the telephone number on this sheet and destroy or return the communication to us at this address. Thank you for your co-operation.


Atty Dkt No. 7011-0032
(APF 32.03)
PATENT

#18
gm
7/18/03

Certificate of Transmission:

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Attention Mail Stop RCE (Fax No. (703) 308-4242) on 11 July 2003.

Printed Name: Thomas P. McCracken


Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

MACKLIN et al.

Serial No.: 09/501,328

Group Art Unit: 1645

Filing Date: 9 February 2000

Examiner: R.P. Schwartz

Title: MYCOBACTERIUM TUBERCULOSIS IMMUNIZATION

**REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL
PURSUANT TO 35 U.S.C. §132(b) AND 37 C.F.R. §1.114**

Sir:

This is a Request for Continued Examination (RCE) under 37 C.F.R. §1.114 of the above-identified application. A Notice of Appeal was filed on 15 January 2003 in the subject application, and this request is being submitted within the extended statutory period for filing the appeal brief.

1. Submission Required under 37 C.F.R. §1.114.

a. Applicants have enclosed herewith:

- i. X Response to final Office Action dated 17 July 2002.
- ii. X Petition for Extension of Time and Fee Therefor.
- iii. Information Disclosure Statement, Form 1449, and cited

references.

Page 1

07/18/2003 JHASON 00000002 500828 09501328

01 FC:1801 750.00 DA
02 FC:2254 1450.00 DA

2. Miscellaneous.

a. Applicants request limited suspension of action on the above-identified application pursuant to 37 C.F.R. §1.103 for a period of _____.

3. Fees.

a. The Director is hereby authorized to charge the following fees to Deposit Account No. 50-0828:


- i. X The RCE fee required under 37 C.F.R. §1.17(e). The RCE fee is \$740.00.
- ii. _____ The fee for Limited Suspension of Action pursuant to 37 C.F.R. §§1.103(c) and 1.17(i). The processing fee is _____.

b. The Commissioner is hereby authorized to charge any further fees which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0828.

Respectfully submitted,

Date: 11 July 2003

By:



Thomas P. McCracken
Registration No. 38,548

POWDERJECT PHARMACEUTICALS PLC
Florey House, The Oxford Science Park
Oxford OX4 4GA
United Kingdom
Telephone: +44 1865 332 600
Fax: +44 1865 332 601